The FDA meeting announcement follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on ...
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab ...
The FDA’s Pharmacy Compounding Advisory Committee will meet this summer to discuss whether certain peptides from compounding ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...
The U.S. Food and Drug Administration (FDA) on Wednesday convened a group of independent advisors to recommend whether to allow compounding pharmacies to manufacture certain peptides. The peptides ...
On March 27, 2026, the Food and Drug Administration (“FDA”) held a public meeting entitled “Exploring the Scope of Dietary Supplement Ingredients.” ...
The Food and Drug Administration (FDA) is taking the first steps toward potentially easing access to certain peptide ...
The US Food and Drug Administration (FDA) on Monday finalized guidance to assist sponsors in their meeting requests with the agency for products subject to product-specific guidance (PSG). The final ...
Quoin Pharmaceuticals (NASDAQ:QNRX) said it received encouraging regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type C meeting held on March 25, 2026 regarding the ...
Kezar Life Sciences is a biotech, not a medical device company, but the mechanics work the same way for any company with a ...
Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results